STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 163903

TO: Shobha Kantamneni **Location: rem/4A10/4B18** **Art Unit: 1617** **Monday, October 24, 2005** **Case Serial Number: 10/675927**	**From: Toby Port** **Location: Biotech-Chem Library** **REM-1A59** **Phone: 571-272-2523** **toby.port@uspto.gov**

Search Notes

Examiner Kantamneni,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Toby Port
X22523

```
=> file reg; d stat que l9
FILE 'REGISTRY' ENTERED AT 11:30:33 ON 24 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 OCT 2005  HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES:  23 OCT 2005  HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html


L6                STR
```



Full file search run on this structure

```
VAR G2=HY/38
```

```
VAR G3=11/28
VAR G4=OH/45/NH2/40/43
VAR G6=H/OH/32/35/27
VAR G7=27/H
VPA 17-8/9 U
NODE ATTRIBUTES:
NSPEC   IS RC     AT  15
NSPEC   IS RC     AT  41
NSPEC   IS RC     AT  42
NSPEC   IS RC     AT  44
NSPEC   IS R      AT  45
CONNECT IS E1  RC AT  27
CONNECT IS E1  RC AT  33
CONNECT IS E1  RC AT  34
CONNECT IS E1  RC AT  36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  35

STEREO ATTRIBUTES: NONE
L9         1179 SEA FILE=REGISTRY SSS FUL L6

100.0% PROCESSED   32662 ITERATIONS                          1179 ANSWERS
SEARCH TIME: 00.00.01



=> file caplus; d que nos l10
FILE 'CAPLUS' ENTERED AT 11:30:52 ON 24 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005  VOL 143 ISS 18
FILE LAST UPDATED: 23 Oct 2005  (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html


L6              STR
L9         1179 SEA FILE=REGISTRY SSS FUL L6
L10           7 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9
```

=> d ibib abs hitstr l10 1-7

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857399 CAPLUS
DOCUMENT NUMBER: 141:343478
TITLE: Use of small molecule compounds for immunopotentiation
INVENTOR(S): Valiante, Nicholas
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087153	A2	20041014	WO 2004-US10331	20040329
WO 2004087153	A3	20050317		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005136065	A1	20050623	US 2004-814480	20040329

PRIORITY APPLN. INFO.: US 2003-458888P P 20030328
OTHER SOURCE(S): MARPAT 141:343478
GI



I

AB The invention provides immunostimulatory compns. comprising a small mol. immunopotentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are compns. and methods of administering SMIP compds. alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. Preparation of selected compds., e.g. I, is included.

IT **611213-07-1 611214-93-8 611215-16-8**
611216-17-2 611223-31-5 774196-96-2
774196-97-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. compds. for immunopotentiation)

RN 611213-07-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-93-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-bicyclohexyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-16-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-17-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611223-31-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 774196-96-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[(trimethylsilyl)ethynyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 774196-97-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



IT **611212-56-7P 611213-70-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(small mol. compds. for immunopotentiation)
RN 611212-56-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-70-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:817883 CAPLUS
DOCUMENT NUMBER: 141:332190
TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors
INVENTOR(S): Dipietro, Lucian V.; Harmange, Jean-Christophe; Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie; Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.; Potashman, Michele; Van der Plas, Simon
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 289 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085425	A1	20041007	WO 2004-US8809	20040322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004209892	A1	20041021	US 2004-804915	20040319
PRIORITY APPLN. INFO.:			US 2003-456691P P	20030321

US 2004-804915 A 20040319

OTHER SOURCE(S): MARPAT 141:332190

GI



I



II

AB Title compds. I [W, X, Y1 and Y2 independently = O, S(O)n and NR3; ring A optionally contains a N atom at a non-fused, non-substituted ring position; n = 0-2; R = (un)substituted-aryl, -heterocyclyl, -fused heterocyclyl, etc.; R1 = (un)substituted-aryl, -arylalkyl, -heterocyclyl, etc.; R2 = H, halo, alkoxy, etc.; R3 = H or alkyl] are prepared and disclosed as having kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Thus, e.g., II was prepared by cyclocondensation of 4-(pyridin-4-yloxy)benzene-1,2-diamine with 1-chloro-4-isothiocyanato-2-trifluoromethylbenzene. In human umbilical vein endothelial cell proliferation assay, selected I inhibited VEGF-stimulated proliferation at a level below 100 nM. Accordingly, I would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmol. conditions, proliferative diseases, inflammatory diseases, and other pathol. conditions as described in the specification.

IT **611212-56-7P 769960-01-2P 769960-02-3P**
769960-03-4P 769960-04-5P 769960-05-6P
769960-06-7P 769960-07-8P 769960-08-9P
769960-09-0P 769960-10-3P 769960-11-4P
769960-12-5P 769960-13-6P 769960-14-7P
769960-15-8P 769960-16-9P 769960-19-2P
769960-20-5P 769960-82-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 611212-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-01-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(pentafluoroethyl)-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 769960-02-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 769960-03-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769960-04-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(pentafluoroethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769960-05-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethyl]-4-methoxyphenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-06-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(difluoromethoxy)-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-07-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-08-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 769960-09-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 769960-10-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 769960-11-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(1-piperazinylmethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-12-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-13-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-14-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769960-15-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-16-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-19-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-6-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-20-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-82-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(1-methyl-2-pyrrolidinyl)methoxy]-4-(pentafluoroethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



IT **769961-00-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)
RN 769961-00-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-chloro-5-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

IT **769961-24-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)
RN 769961-24-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:513393 CAPLUS
DOCUMENT NUMBER: 141:71544
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122237	A1	20040624	US 2003-675927	20030929
US 2004087626	A1	20040506	US 2003-405945	20030331
WO 2005032548	A1	20050414	WO 2004-US32161	20040929

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-369066P	P	20020329
US 2003-405945	A2	20030331
US 2003-675927	A	20030929

OTHER SOURCE(S): MARPAT 141:71544
GI



I



II

AB The title compds. I [wherein X1, X2 = N, NR4, O, S (with provisos); Y = O, S; A1 = (un)substituted alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; A2 = (un)substituted heteroaryl; R1 = O, H; R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted (cyclo)alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, heterocyclyl, (hetero)aryl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl; R7 = alkyl; and pharmaceutically acceptable salts, esters, or prodrugs] were prepared as Raf kinase inhibitors. Examples include synthetic methods and phys. data for 1400 compds., as well as descriptions of two Raf kinase bioassays. For instance, 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide were coupled using potassium bis(trimethylsilyl)amide and K2CO3 in DMF to give 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carboxamide. Pd-catalyzed hydrogenation, followed by cyclization with 4-chloro-3-(trifluoromethyl)benzeneisothiocyanate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl in THF provided the benzimidazole II. One thousand ninety-four compds. inhibited Raf kinase activity with IC50 < 5 μM in a Raf/Mek filtration assay or a biotinylated Raf screen. Thus, I and their pharmaceutical compns., which may comprise at least one addnl. agent, are useful for the treatment of Raf kinase mediated disorders, such as cancer (no data).

IT **611213-97-9P 611214-71-2P 611214-79-0P**
611215-54-4P 611215-68-0P 710351-25-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611213-97-9 CAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 710351-75-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-amino-4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



IT **611226-42-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)
RN 611226-42-7 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:796477 CAPLUS
DOCUMENT NUMBER: 139:307759
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S): Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl, Wendy
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003082272	A1	20031009	WO 2003-US10117		20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2480638	AA	20031009	CA 2003-2480638		20030331
EP 1499311	A1	20050126	EP 2003-745683		20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008854	A	20050222	BR 2003-8854		20030331
JP 2005529089	T2	20050929	JP 2003-579810		20030331
PRIORITY APPLN. INFO.:			US 2002-369066P	P	20020329
			WO 2003-US10117	W	20030331

OTHER SOURCE(S): MARPAT 139:307759

GI



I



II

AB The title compds. [I; X1, X2 = N, NR4, O, S (with the provisos); Y = O, S; A1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; A2 = (un)substituted heteroaryl; R1 = O, H, and R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted alkyl, alkoxyalkyl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl], useful for inhibition of Raf kinase activity in a human or animal subject, were prepared E.g., a 3-step synthesis of the benzimidazole II (starting from 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-

methylcarboxamide), was given. The compds. of examples 1-1094 showed a Raf kinase inhibitory activity at an IC50 of less than 5 μM. A composition comprising the compound I is claimed. The new compds. compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.

IT **611213-97-9P 611214-71-2P 611214-79-0P**
611215-54-4P 611215-68-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611213-97-9 CAPLUS
CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 611214-71-2 CAPLUS
CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 611214-79-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-54-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethynylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-68-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



IT **611212-56-7P 611212-57-8P 611212-58-9P**
611212-59-0P 611212-60-3P 611212-61-4P
611212-62-5P 611212-63-6P 611212-64-7P
611212-65-8P 611212-66-9P 611212-67-0P
611212-68-1P 611212-69-2P 611212-70-5P
611212-71-6P 611212-72-7P 611212-73-8P
611212-74-9P 611212-75-0P 611212-76-1P
611212-77-2P 611212-78-3P 611212-79-4P
611212-80-7P 611212-81-8P 611212-82-9P
611212-83-0P 611212-84-1P 611212-85-2P
611212-86-3P 611212-87-4P 611212-88-5P
611212-89-6P 611212-90-9P 611212-91-0P
611212-92-1P 611212-93-2P 611212-94-3P
611212-95-4P 611212-96-5P 611212-97-6P
611212-98-7P 611212-99-8P 611213-00-4P
611213-01-5P 611213-02-6P 611213-03-7P
611213-04-8P 611213-05-9P 611213-06-0P
611213-07-1P 611213-08-2P 611213-09-3P
611213-10-6P 611213-11-7P 611213-12-8P
611213-13-9P 611213-14-0P 611213-15-1P
611213-16-2P 611213-17-3P 611213-18-4P
611213-19-5P 611213-20-8P 611213-21-9P
611213-22-0P 611213-23-1P 611213-24-2P
611213-25-3P 611213-26-4P 611213-27-5P
611213-28-6P 611213-29-7P 611213-30-0P
611213-31-1P 611213-32-2P 611213-33-3P
611213-34-4P 611213-35-5P 611213-36-6P
611213-37-7P 611213-38-8P 611213-39-9P
611213-40-2P 611213-41-3P 611213-42-4P
611213-43-5P 611213-44-6P 611213-45-7P
611213-46-8P 611213-47-9P 611213-48-0P
611213-49-1P 611213-50-4P 611213-51-5P
611213-53-7P 611213-54-8P 611213-55-9P
611213-56-0P 611213-57-1P 611213-58-2P
611213-60-6P 611213-70-8P 611213-71-9P
611213-72-0P 611213-73-1P 611213-74-2P
611213-75-3P 611213-76-4P 611213-77-5P

611213-78-6P 611213-79-7P 611213-80-0P
611213-81-1P 611213-82-2P 611213-83-3P
611213-84-4P 611213-85-5P 611213-86-6P
611213-87-7P 611213-88-8P 611213-89-9P
611213-90-2P 611213-91-3P 611213-92-4P
611213-93-5P 611213-94-6P 611213-95-7P
611213-96-8P 611213-98-0P 611213-99-1P
611214-00-7P 611214-01-8P 611214-02-9P
611214-03-0P 611214-04-1P 611214-05-2P
611214-06-3P 611214-08-5P 611214-09-6P
611214-10-9P 611214-11-0P 611214-12-1P
611214-13-2P 611214-14-3P 611214-15-4P
611214-16-5P 611214-17-6P 611214-18-7P
611214-19-8P 611214-20-1P 611214-21-2P
611214-22-3P 611214-23-4P 611214-24-5P
611214-25-6P 611214-26-7P 611214-27-8P
611214-28-9P 611214-29-0P 611214-30-3P
611214-31-4P 611214-32-5P 611214-33-6P
611214-34-7P 611214-35-8P 611214-36-9P
611214-37-0P 611214-38-1P 611214-39-2P
611214-40-5P 611214-41-6P 611214-42-7P
611214-43-8P 611214-44-9P 611214-46-1P
611214-47-2P 611214-48-3P 611214-49-4P
611214-50-7P 611214-51-8P 611214-52-9P
611214-53-0P 611214-54-1P 611214-55-2P
611214-56-3P 611214-57-4P 611214-58-5P
611214-59-6P 611214-60-9P 611214-61-0P
611214-62-1P 611214-63-2P 611214-64-3P
611214-65-4P 611214-66-5P 611214-67-6P
611214-68-7P 611214-69-8P 611214-70-1P
611214-72-3P 611214-73-4P 611214-74-5P
611214-75-6P 611214-76-7P 611214-77-8P
611214-78-9P 611214-80-3P 611214-82-5P
611214-83-6P 611214-84-7P 611214-85-8P
611214-86-9P 611214-87-0P 611214-88-1P
611214-89-2P 611214-90-5P 611214-91-6P
611214-92-7P 611214-93-8P 611214-94-9P
611214-95-0P 611214-96-1P 611214-97-2P
611214-98-3P 611214-99-4P 611215-00-0P
611215-01-1P 611215-02-2P 611215-03-3P
611215-04-4P 611215-05-5P 611215-06-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611212-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-57-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-58-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-59-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-60-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-61-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-62-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2-methylpropyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-63-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)-1-naphthalenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-64-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-65-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(benzoylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-66-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(phenylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-67-0 CAPLUS
CN Benzoic acid, 4-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 611212-68-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-69-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-70-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-71-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-72-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-73-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-furanylmethyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-74-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-75-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-76-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-77-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-78-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-79-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-80-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-81-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 611212-82-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611212-83-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-84-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-85-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-86-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-87-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-88-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-89-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-90-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-91-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-92-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-93-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-94-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-95-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-96-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611212-97-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-98-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-biphenyl]-2-ylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-99-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-00-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-01-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-02-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-03-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-04-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-05-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-06-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-07-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-08-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-09-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-10-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-11-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-12-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-13-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-14-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-15-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-16-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-17-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-18-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-19-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-phenoxyphenyl)amino]-1H-

benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-20-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-21-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-22-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-23-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-24-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-25-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-26-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-27-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-28-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-29-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-30-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-31-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-32-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-33-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-34-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-35-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-36-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-37-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-38-8 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethoxy)phenyl]amino]-

1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-39-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(1,3-benzodioxol-5-ylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-40-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-41-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-42-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-43-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-44-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-45-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-46-8 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-47-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-48-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-49-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-50-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-51-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-53-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-methyl-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-54-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-55-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-56-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-57-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-58-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-60-6 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-70-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-71-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-72-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-73-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-74-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-75-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-76-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-77-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-78-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-79-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-80-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-81-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-82-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-83-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-84-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-85-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-86-6 CAPLUS
CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 611213-87-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-88-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-89-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-90-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-91-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-92-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-93-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-94-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-95-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-96-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-98-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(benzoylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-99-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-00-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-01-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-02-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-03-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-04-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-05-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-06-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-08-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-09-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-10-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-11-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-12-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-13-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-14-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-15-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-16-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-17-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-18-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-19-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-biphenyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-20-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-21-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-22-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-23-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-24-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylamino)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-25-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-26-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-27-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-28-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-29-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-30-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-31-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-32-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-33-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-34-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-35-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-36-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-37-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-38-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-39-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(5-oxazolyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-40-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-41-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-42-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(cyclohexylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-43-8 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-44-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-46-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-47-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-48-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(cyclopropylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-49-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-50-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-51-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-52-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethyl-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-53-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-nitrophenoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-54-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(cyclohexylmethyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-55-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-56-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-57-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-58-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-59-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(cycloheptylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-60-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-61-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(bicyclo[2.2.1]hept-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-62-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-63-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-64-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-65-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-66-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-67-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX

NAME)



RN 611214-68-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-69-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-70-1 CAPLUS
CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 611214-72-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethyl-4-isoxazolyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-73-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-methyl-3-phenyl-4-isoxazolyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-74-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-75-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-1H-indazol-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 611214-76-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[(4-methoxyphenyl)methyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-77-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-78-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-80-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-82-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-thienylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-83-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 611214-84-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(1,3-benzodioxol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-85-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-86-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-diethylphenyl)amino]-1-methyl-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-87-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-88-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-89-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-90-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-91-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-92-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-93-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-bicyclohexyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-94-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-95-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-96-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-97-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[5-fluoro-2-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-98-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-phenyl-1H-pyrazol-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 611214-99-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-00-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-01-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-3-oxo-1H-isoindol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-02-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)methylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-03-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(2-naphthalenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-04-4 CAPLUS
CN Carbamic acid, [1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 611215-05-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1H-imidazol-1-yl)propyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-06-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



IT 611215-07-7P 611215-08-8P 611215-09-9P
611215-10-2P 611215-11-3P 611215-12-4P
611215-13-5P 611215-14-6P 611215-15-7P
611215-16-8P 611215-17-9P 611215-18-0P
611215-21-5P 611215-22-6P 611215-23-7P
611215-24-8P 611215-25-9P 611215-26-0P
611215-27-1P 611215-28-2P 611215-29-3P
611215-30-6P 611215-31-7P 611215-32-8P
611215-33-9P 611215-34-0P 611215-35-1P
611215-36-2P 611215-37-3P 611215-38-4P
611215-39-5P 611215-40-8P 611215-41-9P
611215-42-0P 611215-43-1P 611215-44-2P
611215-45-3P 611215-46-4P 611215-47-5P
611215-48-6P 611215-49-7P 611215-50-0P
611215-51-1P 611215-52-2P 611215-53-3P
611215-56-6P 611215-57-7P 611215-58-8P
611215-60-2P 611215-61-3P 611215-62-4P
611215-63-5P 611215-64-6P 611215-65-7P
611215-66-8P 611215-69-1P 611215-70-4P
611215-71-5P 611215-72-6P 611215-73-7P
611215-74-8P 611215-75-9P 611215-76-0P
611215-77-1P 611215-78-2P 611215-79-3P
611215-80-6P 611215-81-7P 611215-82-8P
611215-83-9P 611215-84-0P 611215-85-1P
611215-86-2P 611215-87-3P 611215-88-4P
611215-89-5P 611215-90-8P 611215-91-9P
611215-92-0P 611215-93-1P 611215-94-2P
611215-95-3P 611215-96-4P 611215-98-6P
611215-99-7P 611216-00-3P 611216-01-4P
611216-02-5P 611216-03-6P 611216-04-7P
611216-05-8P 611216-06-9P 611216-07-0P
611216-08-1P 611216-09-2P 611216-10-5P
611216-11-6P 611216-12-7P 611216-13-8P
611216-14-9P 611216-15-0P 611216-16-1P
611216-17-2P 611216-18-3P 611216-19-4P
611216-20-7P 611216-21-8P 611216-22-9P
611216-23-0P 611216-25-2P 611216-26-3P
611216-27-4P 611216-28-5P 611216-29-6P
611216-30-9P 611216-31-0P 611216-32-1P
611216-33-2P 611216-34-3P 611216-35-4P
611216-36-5P 611216-37-6P 611216-39-8P
611216-40-1P 611216-41-2P 611216-42-3P
611216-43-4P 611216-44-5P 611216-45-6P
611216-46-7P 611216-47-8P 611216-48-9P
611216-49-0P 611216-50-3P 611216-51-4P
611216-52-5P 611216-53-6P 611216-54-7P
611216-55-8P 611216-56-9P 611216-57-0P
611216-58-1P 611216-59-2P 611216-60-5P
611216-61-6P 611216-63-8P 611216-64-9P
611216-65-0P 611216-67-2P 611216-68-3P

611216-69-4P 611216-70-7P 611216-71-8P
611216-72-9P 611216-73-0P 611216-74-1P
611216-75-2P 611216-76-3P 611216-77-4P
611216-78-5P 611216-79-6P 611216-80-9P
611216-81-0P 611216-82-1P 611216-84-3P
611216-85-4P 611216-86-5P 611216-87-6P
611216-88-7P 611216-89-8P 611216-91-2P
611216-92-3P 611216-93-4P 611216-94-5P
611216-95-6P 611216-96-7P 611216-97-8P
611216-98-9P 611216-99-0P 611217-00-6P
611217-02-8P 611217-03-9P 611217-43-7P
611217-44-8P 611217-46-0P 611217-47-1P
611217-48-2P 611217-50-6P 611217-51-7P
611217-52-8P 611217-54-0P 611217-55-1P
611217-56-2P 611217-57-3P 611217-58-4P
611217-59-5P 611217-60-8P 611217-62-0P
611217-64-2P 611217-66-4P 611217-67-5P
611217-68-6P 611217-69-7P 611217-70-0P
611217-71-1P 611217-73-3P 611217-75-5P
611217-77-7P 611217-79-9P 611217-81-3P
611217-83-5P 611217-85-7P 611217-88-0P
611217-90-4P 611217-92-6P 611217-94-8P
611217-96-0P 611217-98-2P 611218-00-9P
611218-02-1P 611218-04-3P 611218-07-6P
611218-09-8P 611218-11-2P 611218-13-4P
611218-15-6P 611218-17-8P 611218-19-0P
611218-21-4P 611218-23-6P 611218-25-8P
611218-27-0P 611218-29-2P 611218-30-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611215-07-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-08-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-09-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-10-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[methyl(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-11-3 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-12-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-cyano-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-13-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[1-[(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-14-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-15-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-16-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-17-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-

methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-18-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromo-6-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-21-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(1-isoquinolinylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 611215-22-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-23-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-6-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-24-8 CAPLUS
CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-3-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 611215-25-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-26-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(phenylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-27-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-28-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-29-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1,7-dimethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-30-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-31-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-32-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-33-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-34-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-35-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-36-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-37-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-38-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyano-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-39-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[(4-methylphenyl)methyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-40-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-41-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-42-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methyl[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-43-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-44-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-cyclohexyl-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-45-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1-methyl-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-46-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-amino-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-47-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-48-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylsulfonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-49-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-50-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-51-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-biphenyl]-3-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-52-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-53-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-56-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(7-isoquinolinylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-57-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-58-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-60-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-1-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-61-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-62-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-63-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-64-6 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(1-methylethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-65-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-66-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-cycloheptylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-69-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-[1-oxo-3-(4-pyridinyl)propyl]-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 611215-70-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-71-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-(cyclopentylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-72-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-73-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-74-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-75-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-76-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(diethylamino)propyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-77-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-78-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-79-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(cyclopropylmethyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-80-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-81-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxy-3-pyridinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-82-8 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(2-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-83-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-84-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-85-1 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,4,5-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-86-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-87-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-88-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-89-5 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylpropyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-90-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-91-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-92-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-93-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-94-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-95-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-96-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-98-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-99-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-00-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-01-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-02-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-[(trifluoromethyl)thio]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-03-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-04-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-05-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-06-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(1-methyl-1-phenylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-07-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-08-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-2-(1-methylethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-09-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX

NAME)



RN 611216-10-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-11-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-12-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-13-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-14-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-15-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-16-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-[(cyclohexylmethylamino)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-17-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-

pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-18-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[6-(dimethylamino)-3-pyridinyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-19-4 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(1-methyl-4-piperidinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-20-7 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-21-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(cycloheptylmethyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-22-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,3,5-trimethylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-23-0 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-25-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 611216-24-1
CMF C22 H20 Br N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 611216-26-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 611216-27-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 611216-28-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 611216-29-6 CAPLUS
CN Pyrrolidine, 1-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 611216-30-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-methoxy-4-[[[4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]amino]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-31-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-32-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 611216-33-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-34-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 611216-35-4 CAPLUS
CN 3-Pyrrolidinamine, 1-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 611216-36-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(diphenylmethyl)-3-azetidinyl]- (9CI) (CA INDEX NAME)



RN 611216-37-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-39-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-40-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-41-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-42-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-43-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 611216-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 611216-46-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-3-piperidinyl- (9CI) (CA INDEX NAME)



RN 611216-47-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 611216-48-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 611216-49-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-50-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 611216-51-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)



RN 611216-52-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 611216-53-6 CAPLUS
CN 2-Pyridinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-54-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 611216-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-56-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 611226-14-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:207037 CAPLUS
DOCUMENT NUMBER: 118:207037
TITLE: Determination of methyl 5-hydroxy-2-benzimidazole carbamate in urine by high-performance liquid chromatography with electrochemical detection
AUTHOR(S): Leenheers, L. H.; Engel, R.; Spruit, W. E. T.; Meuling, W. J. A.; Jongen, M. J. M.
CORPORATE SOURCE: Med. Biol. Lab., TNO, Rijswijk, 2280 AA, Neth.
SOURCE: Journal of Chromatography, Biomedical Applications (1993), 613(1), 89-94
CODEN: JCBADL; ISSN: 0378-4347
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A HPLC assay for Me 5-hydroxy-2-benzimidazole carbamate (5-HBC) in urine was developed in order to assess the exposure of workers to the pesticide carbendazim. 5-HBC is measured in urine after hydrolysis, sample clean-up through a strong cation-exchange (SCX) column and extraction with Et acetate. HPLC with electrochem. detection provides selective and sensitive determination of 5-HBC with a detection limit of 5 μg/L. A C18 reversed-phase column was used with 0.06 M ammonium acetate solution (pH 8)-methanol (73:27) as mobile phase. The method was validated with respect to hydrolysis of urine samples, anal. recovery of spiked 5-HBC, stability of 5-HBC conjugates, limit of detection, background and precision. The overall anal. recovery from urine was better than 60%. 5-HBC, excreted in urine as a conjugate, was stable for at least one year when stored at -20°. A background of ca. 5 μg/L was detected in urine from some non-occupationally exposed persons. Between-day coeffs. of variations as calculated from the results of the stability test were 7, 4 and 4% for concns. of 61, 244 and 295 μg/L 5-HBC, resp..

IT **51276-87-0**

RL: ANST (Analytical study)
(as carbendazim metabolites in human urine, methylhydroxybenzimidazole anal. by HPLC in relation to)
RN 51276-87-0 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1975:107204 CAPLUS
DOCUMENT NUMBER: 82:107204
TITLE: Metabolism of thioureidobenzene fungicides in mice and sheep
AUTHOR(S): Douch, P. G. C.
CORPORATE SOURCE: Wallaceville Anim. Res. Cent., Minist. Agric. Fish., Upper Hutt, N. Z.
SOURCE: Xenobiotica (1974), 4(8), 457-75
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Mouse tissue and sheep liver enzyme prepns. metabolized thiophanate (I) [23564-06-9], thiophanate methyl (II) [23564-05-8] and related thioureidobenzene compds. to the benzimidazole derivs. and their 5(6)-hydroxylation products by a mixed function oxidase [9040-60-2] system. The in vitro metabolism to benzimidazole compds. required NADPH [53-57-6], and was inhibited by SKF 525A [62-68-0] and CO [630-08-0]. I and II (0.1 g/kg, orally) were eliminated in vivo partly as Me benzimidazol-2-ylcarbamate [10605-21-7] or Et benzimidazol-2-ylcarbamate [6306-71-4] and their hydroxylated derivs. The hydroxylated metabolites were excreted as glucuronide and sulfate conjugates, and 9-14% of the benzimidazole derivs. were eliminated as conjugates.
IT **51276-87-0 54685-67-5**
RL: FORM (Formation, nonpreparative)
(formation of, by thioureidobenzene fungicides, by sheep and mouse liver)
RN 51276-87-0 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 54685-67-5 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-[(ethoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1974:610 CAPLUS
DOCUMENT NUMBER: 80:610
TITLE: Metabolism of benomyl fungicide in mammals
AUTHOR(S): Douch, P. G. C.
CORPORATE SOURCE: Wallaceville Anim. Res. Cent., Minis. Agric. Fish., Upper Hutt, N. Z.
SOURCE: Xenobiotica (1973), 3(6), 367-80
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Mice, rabbits, and sheep, administered with benomyl (I) [17804-35-2] produced similar patterns of metabolites to those formed by tissue prepns. incubated with I. In all 3 species, 2 metabolites were formed by hydroxylation, and 2 by ester hydrolysis. The hydroxylated metabolites were excreted from all species as the sulfate and glucuronide conjugates. Conjugates with acetic acid were not detected. Approx. 20% of the dose given to each species was eliminated as conjugates of hydroxylated metabolites. Formation of hydroxylated metabolites was inhibited by β-diethylaminoethyl diphenylpropylacetate in vitro. In liver enzyme prepns. from all 3 species, 2-aminobenzimidazole [934-32-7] was hydroxylated to give 5-hydroxy-2-aminobenzimidazole.

IT **51276-87-0**
RL: FORM (Formation, nonpreparative)
(formation of, as benomyl metabolite)
RN 51276-87-0 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> file caold; d que nos l11
FILE 'CAOLD' ENTERED AT 11:33:46 ON 24 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.


L6              STR
L9          1179 SEA FILE=REGISTRY SSS FUL L6
L11            0 SEA FILE=CAOLD ABB=ON  PLU=ON  L9


=> file home
FILE 'HOME' ENTERED AT 11:34:04 ON 24 OCT 2005
```

```
=> d his full

     (FILE 'HOME' ENTERED AT 09:59:06 ON 24 OCT 2005)

     FILE 'CAPLUS' ENTERED AT 09:59:13 ON 24 OCT 2005
               E US2003-675927/APPS
L1           1 SEA ABB=ON  PLU=ON  US2003-675927/AP
               D IALL
               D IALL
               D COS

     FILE 'ZREGISTRY' ENTERED AT 10:15:44 ON 24 OCT 2005
L2             STR

     FILE 'CAPLUS' ENTERED AT 10:48:29 ON 24 OCT 2005
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 10:48:46 ON 24 OCT 2005

     FILE 'CAPLUS' ENTERED AT 10:48:52 ON 24 OCT 2005
L3             TRA L1 1 RN :     1593 TERMS

     FILE 'REGISTRY' ENTERED AT 10:49:00 ON 24 OCT 2005
L4          1593 SEA ABB=ON  PLU=ON  L3
L5          1294 SEA ABB=ON  PLU=ON  L4 AND NCNC2-C6/ES

     FILE 'ZREGISTRY' ENTERED AT 10:57:52 ON 24 OCT 2005
L6             STR L2

     FILE 'REGISTRY' ENTERED AT 11:26:25 ON 24 OCT 2005
L7            50 SEA SSS SAM L6
L8            50 SEA ABB=ON  PLU=ON  L5 AND L7
L9          1179 SEA SSS FUL L6
               SAVE L9 KAN927FU/A TEMP

     FILE 'CAPLUS' ENTERED AT 11:28:41 ON 24 OCT 2005
L10            7 SEA ABB=ON  PLU=ON  L9

     FILE 'CAOLD' ENTERED AT 11:28:59 ON 24 OCT 2005
L11            0 SEA ABB=ON  PLU=ON  L9

     FILE 'REGISTRY' ENTERED AT 11:30:33 ON 24 OCT 2005
               D STAT QUE L9

     FILE 'CAPLUS' ENTERED AT 11:30:52 ON 24 OCT 2005
               D QUE NOS L10
               D IBIB ABS HITSTR L10 1-7

     FILE 'CAOLD' ENTERED AT 11:33:46 ON 24 OCT 2005
               D QUE NOS L1
               D QUE NOS L11

     FILE 'HOME' ENTERED AT 11:34:04 ON 24 OCT 2005


     FILE HOME

     FILE CAPLUS
```

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

FILE ZREGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE CAOLD
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:23:09 ON 25 OCT 2005

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	1.26

FILE 'CAPLUS' ENTERED AT 14:26:41 ON 25 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 24 Oct 2005 (20051024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s 611216-25-2/rn
             2 611216-25-2
             0 611216-25-2D
L1           2 611216-25-2/RN
                 (611216-25-2 (NOTL) 611216-25-2D )

=> d 1-2 ibib abs
```

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:513393 CAPLUS
DOCUMENT NUMBER: 141:71544
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122237	A1	20040624	US 2003-675927	20030929
US 2004087626	A1	20040506	US 2003-405945	20030331
WO 2005032548	A1	20050414	WO 2004-US32161	20040929

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-369066P	P	20020329
US 2003-405945	A2	20030331
US 2003-675927	A	20030929

OTHER SOURCE(S): MARPAT 141:71544

GI



I



II

AB The title compds. I [wherein X1, X2 = N, NR4, O, S (with provisos); Y = O, S; A1 = (un)substituted alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; A2 = (un)substituted heteroaryl; R1 = O, H; R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted (cyclo)alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, heterocyclyl, (hetero)aryl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl; R7 = alkyl; and pharmaceutically acceptable salts, esters, or prodrugs] were prepared as Raf kinase inhibitors. Examples include synthetic methods and phys. data for 1400 compds., as well as descriptions of two Raf kinase bioassays. For instance, 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide were coupled using potassium bis(trimethylsilyl)amide and K2CO3 in DMF to give 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carboxamide. Pd-catalyzed hydrogenation, followed by cyclization with 4-chloro-3-(trifluoromethyl)benzeneisothiocyanate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl in THF provided the benzimidazole II. One thousand ninety-four compds. inhibited Raf kinase activity with IC50 < 5 μM in a Raf/Mek filtration assay or a biotinylated Raf screen. Thus, I and their pharmaceutical compns., which may comprise at least one addnl. agent, are useful for the treatment of Raf kinase mediated disorders, such as cancer (no data).

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2003:796477 CAPLUS
DOCUMENT NUMBER:	139:307759
TITLE:	Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S):	Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl, Wendy
PATENT ASSIGNEE(S):	Chiron Corporation, USA
SOURCE:	PCT Int. Appl., 259 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003082272	A1	20031009	WO 2003-US10117		20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2480638	AA	20031009	CA 2003-2480638		20030331
EP 1499311	A1	20050126	EP 2003-745683		20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008854	A	20050222	BR 2003-8854		20030331
JP 2005529089	T2	20050929	JP 2003-579810		20030331
PRIORITY APPLN. INFO.:			US 2002-369066P	P	20020329
			WO 2003-US10117	W	20030331

OTHER SOURCE(S): MARPAT 139:307759

GI



I



II

AB The title compds. [I; X1, X2 = N, NR4, O, S (with the provisos); Y = O, S; A1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; A2 = (un)substituted heteroaryl; R1 = O, H, and R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted alkyl, alkoxyalkyl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl], useful for inhibition of Raf kinase activity in a human or animal subject, were prepared E.g., a 3-step synthesis of the benzimidazole II (starting from 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide), was given. The compds. of examples 1-1094 showed a Raf kinase inhibitory activity at an IC50 of less than 5 μM. A composition comprising the compound I is claimed. The new compds. compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s 611216-21-8/rn
             2 611216-21-8
             0 611216-21-8D
L2           2 611216-21-8/RN
                 (611216-21-8 (NOTL) 611216-21-8D )

=> s 611213-97-9/rn
             2 611213-97-9
             0 611213-97-9D
L3           2 611213-97-9/RN
                 (611213-97-9 (NOTL) 611213-97-9D )

=> s 611213-23-1/rn
             2 611213-23-1
             0 611213-23-1D
L4           2 611213-23-1/RN
                 (611213-23-1 (NOTL) 611213-23-1D )

=> e amiri/au
E1           6     AMIRHOR PARVIZ/AU
E2           3     AMIRHUSIN BAHAGIAWATI/AU
E3           0 --> AMIRI/AU
E4          16     AMIRI A/AU
E5           1     AMIRI A KARIM/AU
E6           1     AMIRI ABDUL/AU
E7           1     AMIRI ABDULLAH MOHAMMED/AU
E8           2     AMIRI AFSANEH/AU
E9           4     AMIRI AHMAD/AU
E10          2     AMIRI ALI ASGHAR/AU
E11          3     AMIRI ALI S/AU
E12          1     AMIRI ALI SAFARZADEH/AU

=> e payman/au
E1           7     PAYMAL JEAN/AU
E2           1     PAYMAL JEAN ANDRE/AU
E3           0 --> PAYMAN/AU
E4           1     PAYMAN FRANK L/AU
E5           1     PAYMAN GARY H/AU
E6          21     PAYMAN J B/AU
E7           2     PAYMAN JOSEPH/AU
E8           9     PAYMAN JOSEPH B/AU
E9           1     PAYMAN L C/AU
E10          2     PAYMAN LAURENCE C/AU
E11          2     PAYMAN P W/AU
E12          1     PAYMAN S/AU

=> e renhowe/au
E1           5     RENHORN INGMAR/AU
E2           1     RENHORN INGMAR G E/AU
E3           0 --> RENHOWE/AU
E4           2     RENHOWE PAUL/AU
E5          25     RENHOWE PAUL A/AU
E6           1     RENHOWE PAUL ALLAN/AU
E7           1     RENHUA CHEN/AU
E8           1     RENHUA HUANG/AU
E9           1     RENHUA LAN/AU
E10          1     RENHUA WANG/AU
E11          1     RENHUA YANG/AU
E12          1     RENHUN LI/AU

=> s e4 or e5 or e6
             2 "RENHOWE PAUL"/AU
            25 "RENHOWE PAUL A"/AU
```

```
             1 "RENHOWE PAUL ALLAN"/AU
L5          28 "RENHOWE PAUL"/AU OR "RENHOWE PAUL A"/AU OR "RENHOWE PAUL ALLAN"
               /AU

=> dup rem L5
PROCESSING COMPLETED FOR L5
L6           28 DUP REM L5 (0 DUPLICATES REMOVED)

=> s L5 and (PY<2002 or pry<2002 or AY<2002)
      21804119 PY<2002
       3580839 PRY<2002
       3650665 AY<2002
L7           19 L5 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> d 1-19 ibib abs

L7   ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2003:98039  CAPLUS
DOCUMENT NUMBER:          138:153534
TITLE:                    Preparation of benzimidazolyl-substituted quinolinone
                          derivatives and analogs, with inhibitory action
                          against vascular endothelial growth factor receptor
                          tyrosine kinase, and useful as anticancer agents
INVENTOR(S):              Renhowe, Paul A.; Pecchi, Sabina;
                          Machajewski, Timothy D.; Shafer, Cynthia M.; Taylor,
                          Clarke; McCrea, William R.; McBride, Christopher;
                          Jazan, Elisa
PATENT ASSIGNEE(S):       Chiron Corporation, USA
SOURCE:                   U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S.
                          Pat. Appl. 2002 107,392.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2003028018         A1    20030206    US 2002-116117          20020405 <--
     US 2002107392         A1    20020808    US 2001-951265          20010911 <--
     US 6605617            B2    20030812
     US 2003158224         A1    20030821    US 2002-284017          20021030 <--
     US 6774237            B2    20040810
     US 2004006101         A1    20040108    US 2003-387355          20030312 <--
     US 6762194            B2    20040713
     CA 2481055            AA    20031023    CA 2003-2481055         20030404
     WO 2003087095         A1    20031023    WO 2003-US10463         20030404
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1497287            A1    20050119    EP 2003-746614          20030404
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003008996         A     20050222    BR 2003-8996            20030404
     JP 2005527587         T2    20050915    JP 2003-584051          20030404
     US 2004097545         A1    20040520    US 2003-613411          20030703 <--
     US 6800760            B2    20041005
     US 2005054672         A1    20050310    US 2004-886950          20040708 <--
```

US 2005209456	A1	20050922	US 2005-92137		20050329 <--
PRIORITY APPLN. INFO.:			US 2000-232159P	P	20000911 <--
			US 2001-951265	A2	20010911 <--
			US 2002-116117	A	20020405
			US 2002-284017	A1	20021030
			WO 2003-US10463	W	20030404
			US 2004-886950	A1	20040708

OTHER SOURCE(S): MARPAT 138:153534
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. of formulas I and II are provided [for I: Z = O, S, (un)substituted NH; Y = certain OH derivs., CHO, esters and amides of CO2H, certain NH2 derivs.; R1-R4 = H, halo, cyano, NO2, OH or derivs., NH2 or derivs., (un)substituted amidinyl, guanidinyl, alk(en/yn)yl, aryl, heterocyclyl, CHO, CO2H and esters and amides; R5-R8 = H, halo, NO2, OH or derivs., NH2 or derivs., SH or derivs., cyano, etc.; R9 = H, OH, (un)substituted alkoxy or aryloxy, NH2 or derivs., (un)substituted alkyl or aryl, CHO, alkanoyl, aroyl; for II: A, B, D, E = C or N, with at least one being N; Y = H, OH or derivs., SH or derivs., NH2 or derivs., cyano, various acyl groups, (un)substituted alk(en/yn)yl, aralkyl, heterocycloalkyl, aryl, etc.; R1-R8 = H, halo, NO2, cyano, OH or derivs., NH2 or derivs., acyl, SH or derivs., etc.; R9 = H, OH, (un)substituted alkoxy, aryloxy, NH2 or derivs., aryl, CHO, alkanoyl, aroyl]. Also provided are pharmaceutical formulations including the compds. or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, which may be prepared by mixing the compds. or salts with a carrier and water. A disclosed method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient. Claims include tautomers of the compds., pharmaceutically acceptable salts, and pharmaceutically acceptable salts of the tautomers. I and II are inhibitors of receptor tyrosine kinases, and particularly of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. As such, they are inhibitors of angiogenesis, and thereby act as anticancer agents. Approx 270 invention compds. are listed, with detailed prepns. given for about 50 compds. Several general preparatory methods are discussed in detail. For instance, cyclocondensation of Et 2-(benzimidazol-2-yl)acetate with the corresponding ortho-amino nitrile (prepns. given), carried out in refluxing ClCH2CH2Cl in the presence of SnCl4, gave the invention quinolinone III. Many compds. I and II had in vitro IC50 values of less than 10 μM with respect to flt-1 (VEGFR1), KDR (VEGFR2) and bFGF kinases (recombinant, expressed in Sf9 insect cells).

L7 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2003:42265 CAPLUS
DOCUMENT NUMBER:	138:106699
TITLE:	Preparation of (indazolyl)benzimidazoles and analogs as tyrosine and serine/threonine kinase inhibitors
INVENTOR(S):	**Renhowe, Paul A.**; Shafer, Cynthia M.; McBride, Chris; Silver, Joel; Pecchi, Sabina; Machajewski, Tim; Mccrea, Bill; Poon, Daniel; Thomas, Teresa
PATENT ASSIGNEE(S):	Chiron Corporation, USA
SOURCE:	PCT Int. Appl., 435 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004488	A1	20030116	WO 2002-US20844	20020702 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207883	A1	20031106	US 2002-187967	20020702 <--
EP 1401831	A1	20040331	EP 2002-752132	20020702 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004536113	T2	20041202	JP 2003-510655	20020702 <--
PRIORITY APPLN. INFO.:			US 2001-302791P P	20010703 <--
			WO 2002-US20844 W	20020702

OTHER SOURCE(S): MARPAT 138:106699

GI



I

AB Title compds. I [wherein Z1-Z4 = C independently C or N; R1 = H, F, Cl, or Br; R2 = H, F, Cl, Br, CN, NO2, or (un)substituted CO2H, NH2, CONH2, NHCONH2, etc.; R3 = H, F, Cl, Br, or (un)substituted alkoxy; R4, R9, and R10 = H; R5 and R8 = independently H, F, Cl, or (un)substituted alkyl, alkoxy, NH2, heterocyclyl, etc.; R6 and R7 = independently H, F, Cl, Br, CF3, CO2H, or (un)substituted alkyl, (heterocyclyl)alkoxy, arylalkoxy, alkoxyalkoxy, (heterocyclyl)heterocyclyl, arylheterocyclyl, heterocyclyloxy, aryloxy, NH2, CONH2, etc.; or R5 is absent if Z1 = N; or R6 is absent if Z2 = N; or R7 is absent if Z3 = N; or R8 is absent if Z4 = N; with the proviso that at least one of R1, R2, R3, R5, R6, R7, or R8 ≠ H; and tautomers and pharmaceutically acceptable salts thereof] were prepared as tyrosine and serine/threonine kinase inhibitors. For example, dimerization of indazole-3-carboxylic acid with PO3 followed by addition of 1,2-phenylenediamine in toluene gave 3-(1H-benzimidazol-2-yl)-1H-indazole. Seven hundred twenty-eight exemplary compds. were assays for serine/threonine kinase activity in vitro, and the majority displayed an IC50 value of less than 10 μM with respect to VEGFR1, Flk-1, bFGF, Tie-2, CHK-1, cdc2, GSK-3, NEK-2, and PDGF.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:220574 CAPLUS

DOCUMENT NUMBER: 136:263158
TITLE: Benzimidazolyl-substituted quinolinone derivatives and analogs, with inhibitory action against vascular endothelial growth factor receptor tyrosine kinase, and useful as anticancer agents
INVENTOR(S): **Renhowe, Paul**; Pecchi, Sabina; Machajewski, Tim; Shafer, Cynthia; Taylor, Clarke; McCrea, Bill; McBride, Chris; Jazan, Elisa; Wernette-Hammond, Mary-Ellen; Harris, Alex
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022598	A1	20020321	WO 2001-US42131	20010911 <--
WO 2002022598	C1	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421120	AA	20020321	CA 2001-2421120	20010911 <--
AU 2001093275	A5	20020326	AU 2001-93275	20010911 <--
EP 1317442	A1	20030611	EP 2001-973722	20010911 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013757	A	20040302	BR 2001-13757	20010911 <--
JP 2004509112	T2	20040325	JP 2002-526851	20010911 <--
NZ 524717	A	20040924	NZ 2001-524717	20010911 <--
ZA 2003001578	A	20040826	ZA 2003-1578	20030226 <--
NO 2003001097	A	20030325	NO 2003-1097	20030310 <--
US 2004006101	A1	20040108	US 2003-387355	20030312 <--
US 6762194	B2	20040713		
BG 107709	A	20040130	BG 2003-107709	20030408 <--
US 2005054672	A1	20050310	US 2004-886950	20040708 <--
US 2005209456	A1	20050922	US 2005-92137	20050329 <--

PRIORITY APPLN. INFO.:	US 2000-232159P	P	20000911 <--
	US 2001-951265	A1	20010911 <--
	WO 2001-US42131	W	20010911 <--
	US 2002-284017	A1	20021030
	US 2004-886950	A1	20040708

OTHER SOURCE(S): MARPAT 136:263158
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. of formulas I and II are provided [for I: Z = O, S, (un)substituted NH; Y = certain OH derivs., CHO, esters and amides of CO2H, certain NH2 derivs.; R1-R4 = H, halo, cyano, NO2, OH or derivs., NH2 or derivs., (un)substituted amidinyl, guanidinyl, alk(en/yn)yl, aryl, heterocyclyl, CHO, CO2H and esters and amides; R5-R8 = H, halo, NO2, OH or derivs., NH2 or derivs., SH or derivs., cyano, etc.; R9 = H, OH, (un)substituted alkoxy or aryloxy, NH2 or derivs., (un)substituted alkyl

or aryl, CHO, alkanoyl, aroyl; for II: A, B, D, E = C or N, with at least one being N; Y = H, OH or derivs., SH or derivs., NH2 or derivs., cyano, various acyl groups, (un)substituted alk(en/yn)yl, aralkyl, heterocycloalkyl, aryl, etc.; R1-R8 = H, halo, NO2, cyano, OH or derivs., NH2 or derivs., acyl, SH or derivs., etc.; R9 = H, OH, (un)substituted alkoxy, aryloxy, NH2 or derivs., aryl, CHO, alkanoyl, aroyl]. Also provided are pharmaceutical formulations including the compds. or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, which may be prepared by mixing the compds. or salts with a carrier and water. A disclosed method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient. Claims include tautomers of the compds., pharmaceutically acceptable salts, and pharmaceutically acceptable salts of the tautomers. I and II are inhibitors of receptor tyrosine kinases, and particularly of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. As such, they are inhibitors of angiogenesis, and thereby act as anticancer agents. Approx 270 invention compds. are listed, with detailed prepns. given for about 50 compds. Several general preparatory methods are discussed in detail. For instance, cyclocondensation of Et 2-(benzimidazol-2-yl)acetate with the corresponding ortho-amino nitrile (prepns. given), carried out in refluxing ClCH2CH2Cl in the presence of SnCl4, gave the invention quinolinone III. Many compds. I and II had in vitro IC50 values of less than 10 μM with respect to flt-1 (VEGFR1), KDR (VEGFR2) and bFGF kinases (recombinant, expressed in Sf9 insect cells).

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:171899 CAPLUS
DOCUMENT NUMBER: 136:232301
TITLE: Preparation of heterocyclic compounds as vascular endothelial growth factor receptor tyrosine kinase inhibitors
INVENTOR(S): **Renhowe, Paul**; Machajewski, Tim; Shafer, Cynthia; Wernette-Hammond, Mary-ellen; Harris, Alex
PATENT ASSIGNEE(S): Chiron Corporation, USA; Pecci Sabina
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018383	A2	20020307	WO 2001-US41942	20010830 <--
WO 2002018383	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001093233	A5	20020313	AU 2001-93233	20010830 <--
US 2002103230	A1	20020801	US 2001-943382	20010830 <--
US 6756383	B2	20040629		
EP 1313734	A2	20030528	EP 2001-973678	20010830 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507543	T2	20040311	JP 2002-523898	20010830 <--
US 2004002518	A1	20040101	US 2003-452786	20030602 <--

US 6759417	B2	20040706			
US 2005137188	A1	20050623	US 2004-823995		20040414 <--
PRIORITY APPLN. INFO.:			US 2000-231829P	P	20000901 <--
			US 2001-943382	A3	20010830 <--
			WO 2001-US41942	W	20010830 <--
			US 2003-452786	A1	20030602

OTHER SOURCE(S): MARPAT 136:232301

GI



I



II

AB Heterocyclic compds. of formula I [Y = OH, SH, NH2, CN, acyl, etc.; Z = O, S, NH; R1R2 = 5-7 membered ring comprising at least one O, N or S atom; R3 = H, OH, alkoxy, NH2, alkyl, etc.; R4-R7 = H, Cl, Br, F, I, NO2, CN, OH, acyl, etc.] are prepared The compds. are inhibitors of vascular endothelial growth factor receptor tyrosine kinase. Thus, II was prepared from 3-aminopyridine-4-carboxylic acid, Me 2-(chlorocarbonyl)acetate and 1,2-phenylenediamine. The prepared compds. displayed an IC50 value of less than 10 μM against various protein tyrosine kinases.

L7 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2002:171845 CAPLUS
DOCUMENT NUMBER:	136:232121
TITLE:	Preparation of guanidinobenzamides as melanocortin-4 receptor agonists useful for treating diseases such obesity and type II diabetes
INVENTOR(S):	**Renhowe, Paul A.**; Chu, Daniel; Boyce, Rustum; Ni, Zhi-jie; Duhl, David; Tozzo, Effie; Johnson, Kirk; Myles, David
PATENT ASSIGNEE(S):	Chiron Corporation, USA
SOURCE:	PCT Int. Appl., 145 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018327	A2	20020307	WO 2001-US27206	20010831 <--
WO 2002018327	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420694	AA	20020307	CA 2001-2420694	20010831 <--
AU 2001088604	A5	20020313	AU 2001-88604	20010831 <--

US 2002137939	A1	20020926	US 2001-945384		20010831 <--
US 6638927	B2	20031028			
SI 21267	C	20040229	SI 2001-20058		20010831 <--
BR 2001013643	A	20040302	BR 2001-13643		20010831 <--
JP 2004508304	T2	20040318	JP 2002-523445		20010831 <--
EP 1409468	A2	20040421	EP 2001-968352		20010831 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NZ 524897	A	20040827	NZ 2001-524897		20010831 <--
ZA 2003001544	A	20040622	ZA 2003-1544		20030225 <--
NO 2003000929	A	20030430	NO 2003-929		20030227 <--
US 2003199499	A1	20031023	US 2003-379397		20030304 <--
BG 107639	A	20031128	BG 2003-107639		20030318 <--
PRIORITY APPLN. INFO.:			US 2000-230565P	P	20000831 <--
			US 2000-245579P	P	20001106 <--
			US 2001-945384	A3	20010831 <--
			WO 2001-US27206	W	20010831 <--

OTHER SOURCE(S): MARPAT 136:232121

GI



I



II

AB Compds. I and II, e.g. [4-[((1Z)-2-aza-2-cyclopentyl-1-piperazinylvinyl)amino]phenyl]-N-[2-(2,4-dichlorophenyl)ethyl]carboxamide, are new where the variables R1 through R10 have the values set forth below. Such compds. and prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof. have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier. In I and II, R1 is H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R2 is substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R3 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. R4 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; R5 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; or R4 and R5, together with

the N to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group; R6, R7, R8, and R9 may be the same or different, and are each independently H, Cl, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; R10 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups. Although the methods of preparation are not claimed, .apprx.60 example prepns., involving resin- and non-resin-based methods, are included. EC50 values of test compds. were determined by treating cells expressing MC4-R with test compound and lyzing the cells and measuring intercellular cAMP concentration with Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. Compds. listed displayed -log EC50 values .gtorsim.3. In vivo studies were conducted using mice to observe the effect of MC4-R agonists on energy intake, body weight, hyperinsulinemia, and glucose levels; results are given for 4-[(N-cyclohexyl-3,5-dimethylpiperazine-1-carboximidoyl)amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide.

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:674646 CAPLUS
DOCUMENT NUMBER: 135:313056
TITLE: Growth factor receptor kinases in cancer
AUTHOR(S): **Renhowe, Paul A.**
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608-2916, USA
SOURCE: Annual Reports in Medicinal Chemistry (**2001**), 36, 109-118
CODEN: ARMCBI; ISSN: 0065-7743
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review, with 93 refs., focuses on the ATP-competitive inhibitors of the growth factor-receptor tyrosine kinases. Topics discussed include epidermal, platelet-derived, fibroblast, and vascular endothelial growth factor receptor tyrosine kinase inhibitors. The number of kinases expressed throughout the body will make it difficult to determine the inhibitory profile of any compound designed to inhibit specific members of this class of enzymes. (c) 2001 Academic Press.
REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:293395 CAPLUS
DOCUMENT NUMBER: 133:43696
TITLE: A Practical Entry to the Crambescidin Family of Guanidine Alkaloids. Enantioselective Total Syntheses of Ptilomycalin A, Crambescidin 657 and Its Methyl Ester (Neofolitispates 2), and Crambescidin 800
AUTHOR(S): Coffey, D. Scott; McDonald, Andrew I.; Overman, Larry E.; Rabinowitz, Michael H.; **Renhowe, Paul A.**
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: Journal of the American Chemical Society (**2000**), 122(20), 4893-4903
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:43696
AB Among the most structurally remarkable guanidine natural products are the crambescidin/ptilomycalin A family of marine alkaloids. The evolution of a practical strategy for preparing pharmacol. significant crambescidin/ptilomycalin A alkaloids that lack oxidation at C13 is

described. The first total syntheses of crambescidin 800 (2), crambescidin 657 (6), and neofolitispate 2 (7) are reported in full detail. The central strategic step in these convergent total syntheses is tethered Biginelli condensation of a β-keto ester with an ureido aminal to combine all carbons of the guanidine nucleus and set the pivotal C10-C13 stereo-relationship. The total synthesis of crambescidin 800 was accomplished in 3% overall yield from com. available 3-butyn-1-ol by way of 16 isolated and purified intermediates. Full details of our earlier total synthesis of ptilomycalin A (1) are also presented. The total syntheses described in this disclosure confirm the stereochem. assignments of 1, 2, 6, and 7 and rigorously establish that the absolute configuration of the hydroxyspermidine side chain of crambescidin 800 is S.

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:812696 CAPLUS
DOCUMENT NUMBER: 132:92807
TITLE: Advances in solid-supported organic synthesis methods, 1998 to 1999
AUTHOR(S): Nuss, John M.; **Renhowe, Paul A.**
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608, USA
SOURCE: Current Opinion in Drug Discovery & Development (**1999**), 2(6), 631-650
CODEN: CODDFF; ISSN: 1367-6733
PUBLISHER: Current Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 69 refs. is given. Combinatorial chemical is now regarded as an important component of the drug discovery process and is increasingly having an impact in other areas of the chemical sciences, such as catalysis and materials science. Solid-supported organic synthesis continues to be an integral component in the efficient assembly of combinatorial libraries. This review attempts to describe some of the most important recent developments in solid-supported organic synthesis during the period 1998 to 1999. Particular emphasis is placed on the development of novel, efficient methods for the synthesis of diverse, non-oligomeric libraries and structurally complex mols.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:811233 CAPLUS
DOCUMENT NUMBER: 132:64265
TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithry; **Renhowe, Paul A.**; Seely, Lynn; Subramanian, Sharadha; Wagman, Allan S.; Zhou, Xiaohui A.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965897	A1	19991223	WO 1999-US13809	19990618 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9949566	A1	20000105	AU 1999-49566		19990618 <--
EP 1087963	A1	20010404	EP 1999-933522		19990618 <--
EP 1087963	B1	20040825			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 6489344	B1	20021203	US 1999-336098		19990618 <--
JP 2003527303	T2	20030916	JP 2000-554722		19990618 <--
AT 274510	E	20040915	AT 1999-933522		19990618 <--
US 2003130289	A1	20030710	US 2002-309535		20021203 <--
PRIORITY APPLN. INFO.:			US 1998-89978P	P	19980619 <--
			US 1999-336098	A3	19990618 <--
			WO 1999-US13809	W	19990618 <--

OTHER SOURCE(S): MARPAT 132:64265
GI



II

AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:499760 CAPLUS
DOCUMENT NUMBER: 131:257831
TITLE: Investigations of a Nucleophilic Alaninol Synthon Derived from Serine
AUTHOR(S): Sibi, Mukund P.; Rutherford, Drew; **Renhowe, Paul A.**; Li, Biqin
CORPORATE SOURCE: Department of Chemistry, North Dakota State University, Fargo, ND, 58105-5516, USA
SOURCE: Journal of the American Chemical Society (**1999**), 121(33), 7509-7516
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:257831
AB A nucleophilic synthon, (S)-(+)-4-(2-oxazolidonyl)-methyltriphenylphosphinyl iodide, available from L-serine in five steps

(overall yield of 52%), reacts with aldehydes to produce alkenes in good to excellent yields (74-89%) and, in some cases, provides excellent stereocontrol of the new double bond. The geometry of the newly formed double bond is influenced by the nature of the aldehyde and reaction conditions. The trends in olefin configuration are discussed. Application of this methodol. allows for easy preparation of mols. containing double bonds allylic to nitrogen, including oxazolidinones and β,γ-unsatd. amino alcs. Several of the unsatd. oxazolidinones are converted to β,γ-unsatd. amino alcs. in high yields (75 to 90%).

REFERENCE COUNT: 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:226492 CAPLUS
DOCUMENT NUMBER: 126:199384
TITLE: Total Synthesis of (+)-Isolaurepinnacin. Use of Acetal-Alkene Cyclizations To Prepare Highly Functionalized Seven-Membered Cyclic Ethers
AUTHOR(S): Berger, Daniel; Overman, Larry E.; **Renhowe, Paul A.**
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: Journal of the American Chemical Society (**1997**), 119(10), 2446-2452
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The first synthesis of title compound I [R = CH2CH:CHC.tplbond.CH-(E)] is described. The synthesis features an acetal-vinylsilane cyclization to stereoselectively form the cis-2,7-disubstituted oxepene ring and introduce Δ4-unsatn. Starting with (2R,3S)-2,3-epoxypentan-1-ol, mixed acetal II is formed in five steps and 72% overall yield. Treatment of II with excess BCl3 in CH2Cl2 at -78 → 0 °C promotes cyclization to afford Δ4-oxepene I (R = CH2CH2CH2OH) in 90% yield after deprotection of the silyl ether. Elaboration of the (E)-enyne functionality of the six-carbon side chain completes the synthesis of (+)-isolaurepinnacin.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:218872 CAPLUS
DOCUMENT NUMBER: 126:293272
TITLE: Developing a general strategy for the solid supported synthesis of heterocycles: applications to the generation of molecular diversity and drug discovery
AUTHOR(S): Nuss, John M.; Desai, Manoj C.; Zuckermann, Ronald N.;

Singh, Rajinder; **Renhowe, Paul A.**; Goff, Dane A.; Chinn, Jason P.; Wang, Liang; Dorr, Hilary; Brown, Edward G.; Subramanian, Sharadha

CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA

SOURCE: Pure and Applied Chemistry (**1997**), 69(3), 447-452
CODEN: PACHAS; ISSN: 0033-4545
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB The development of a general strategy for the generation of mol. diversity in the form of novel, non-amide based heterocyclic structures is described with 19 refs. The generation of diverse peptide and peptidomimetic libraries, the automation of these strategies and computational approaches to diversity generation are also discussed. The main focus of this lecture is the progression of these concepts into a strategy for small mol. library generation, and hence the generation of small mol. therapeutic leads.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:141020 CAPLUS
DOCUMENT NUMBER: 126:157521

TITLE: Combinatorial libraries of substrate-bound cyclic organic compounds

INVENTOR(S): Desai, Manoi C.; Nuss, John M.; Spear, Kerry L.; Singh, Rajinder; **Renhowe, Paul A.**; Brown, Edward G.; Richter, Lutz; Scott, Barbara O.

PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640201	A1	19961219	WO 1996-US7684	19960523 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
US 5958792	A	19990928	US 1995-485006	19950607 <--
CA 2221508	AA	19961219	CA 1996-2221508	19960523 <--
AU 9659320	A1	19961230	AU 1996-59320	19960523 <--
EP 777492	A1	19970611	EP 1996-916633	19960523 <--
EP 777492	B1	20050119		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1192154	A	19980902	CN 1996-195924	19960523 <--
JP 2001518053	T2	20011009	JP 1997-500720	19960523 <--
AT 287417	E	20050215	AT 1996-916633	19960523 <--

PRIORITY APPLN. INFO.: US 1995-485006 A 19950607 <--
WO 1996-US7684 W 19960523 <--

OTHER SOURCE(S): MARPAT 126:157521

GI



I



II

AB The invention relates to libraries of cyclic organic compds. and methods of producing and assaying such libraries. According to the invention, each cyclic organic compound is constructed from a starting material in the form of a solid surface derivatized with a starting resin. Compds. are reacted with the resin to add or form a cyclic group. The reactions are preferably carried out using a split resin procedure so that different compds. can be reacted with a plurality of subamounts so as to increase the size of the library. For example, compds. are reacted with a solid support bound starting resin to obtain a compound which includes an aldehyde functional group wherein the aldehyde compound or compds. reacted with it have substituents which are varied such that a mixture of products is obtained. The invention further relates to methods of producing combinatorial libraries of cyclic organic compds. from substrate bound compds. by cleaving the compds. from the support after synthesizing is completed and to assaying libraries of such compds. Several actual examples show the construction of aromatic and heterocyclic organic compds. on Rink amide resins. Addnl. prophetic examples show the preparation of libraries by analogous methods. For instance, the Rink amide resin-bound aldehyde Resin-NHCOC6H4CHO-4 was cyclized with sarcosine and di-Me muconate at 110°, and the product was worked up and cleaved from the support with CF3CO2H in CH2Cl2, to give a total of 4 isomers of the target compds. I and II.

L7 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:852174 CAPLUS
DOCUMENT NUMBER: 123:286366
TITLE: Enantioselective total synthesis of (+)-isolaurepinnacin and enantioselective total synthesis of (-)-ptilomycalin a
AUTHOR(S): **Renhowe, Paul Allan**
CORPORATE SOURCE: Univ. of California, Irvine, CA, USA
SOURCE: (**1995**) 148 pp. Avail.: Univ. Microfilms Int., Order No. DA9525158
From: Diss. Abstr. Int., B 1995, 56(3), 1429
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable

L7 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:397708 CAPLUS
DOCUMENT NUMBER: 122:291250
TITLE: Enantioselective Total Synthesis of (-)-Ptilomycalin A
AUTHOR(S): Overman, Larry E.; Rabinowitz, Michael H.;

Renhowe, Paul A.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92717-2025, USA
SOURCE: Journal of the American Chemical Society (**1995**), 117(9), 2657-8
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:291250
GI



I

AB The total synthesis of the title compound (I) was accomplished in a convergent from three readily available enantioenriched secondary alcs.

L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:508932 CAPLUS
DOCUMENT NUMBER: 121:108932
TITLE: Regioselective Opening of Terminal Epoxides with 2-(Trialkylsilyl)allyl Organometallic Reagents
AUTHOR(S): Overman, Larry E.; **Renhowe, Paul A.**
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92717-2025, USA
SOURCE: Journal of Organic Chemistry (**1994**), 59(15), 4138-42
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:108932
AB Terminal epoxides react with 2-(trialkylsilyl)allyl organometallics (Sn, Si, Li, Cu) with varying degrees of efficiency depending upon the nature of the epoxide. The combination of [2-(trimethylsilyl)allyl]tributylstann ane and EtAlCl2 is optimum and, in general, provides 1-substituted 4-(trimethylsilyl)-4-penten-1-ol products, e.g. CH2:C(SiMe2Ph)CH2CH2CHOHBu, in good yield.

L7 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:670893 CAPLUS
DOCUMENT NUMBER: 119:270893
TITLE: Enantioselective total synthesis of (+)-isolaurepinnacin
AUTHOR(S): Berger, Daniel; Overman, Larry E.; **Renhowe, Paul**

A.

CORPORATE SOURCE: Dep. Chem., Univ. California, Irvine, CA, 92717-2025, USA

SOURCE: Journal of the American Chemical Society (**1993**), 115(20), 9305-6
CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 119:270893

GI



I



II

AB The total synthesis of (+)-isolaurepinnacin (I) was accomplished in 12 total steps and 15% overall yield from cis-2-penten-1-ol. This total synthesis rigorously establishes the S configuration of I at C(13), which had previously been assigned on biosynthetic grounds only, and corrects the rotation of I to be dextrorotatory. The key step is the completely stereocontrolled cyclization of the mixed acetal II to provide the cis-2,7-disubstituted-Δ4-oxepene in 90% yield. This conversion highlights the extraordinary selectivity that can be realized in acetal-alkene cyclizations and demonstrates that chiral α-chloro oxocarbenium ions are sufficiently configurationally stable to not epimerize during a favorable acetal-alkene cyclization.

L7 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:490556 CAPLUS

DOCUMENT NUMBER: 117:90556

TITLE: A novel thermolytic annulation of an oxazolidinone: an enantiospecific synthesis of (-)-slaframine

AUTHOR(S): Sibi, Mukund P.; Christensen, James W.; Li, Biqin; **Renhowe, Paul A.**

CORPORATE SOURCE: Dep. Chem., North Dakota State Univ., Fargo, ND, 58105, USA

SOURCE: Journal of Organic Chemistry (**1992**), 57(16), 4329-30
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:90556

GI



I



II



III



IV

AB The stereospecific syntheses of (-)-slaframine (I) and (-)-8a-epidesacetoxyslaframine (II) from (+)-N-BOC-3-hydroxyproline Et ester and (-)-N-BOC-proline Me ester, resp., through a thermolytic annulation of oxazolidinones III and IV, resp. illustrates an efficient general method for the formation of the β-amino piperidine structure. (-)-Slaframine was prepared in 27% overall yield from (+)-N-BOC-3-hydroxyproline Et ester, and (-)-8a-epidesacetoxyslaframine was prepared in 59% overall yield from (-)-N-BOC-proline Me ester. The yields for the key thermolytic annulations were 92% and 83% resp. The convergent method is applicable to gram scale prepns., and has the potential for stereoisomer and analog preparation

L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:143961 CAPLUS
DOCUMENT NUMBER: 114:143961
TITLE: A new nucleophilic alaninol synthon from serine
AUTHOR(S): Sibi, Mukund P.; **Renhowe, Paul A.**
CORPORATE SOURCE: Dep. Chem., North Dakota State Univ., Fargo, ND, 58105, USA
SOURCE: Tetrahedron Letters (**1990**), 31(51), 7407-10
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:143961
GI



I



II

AB A new nucleophilic alaninol synthon (I) derived from serine is reported. The utility of I in the stereoselective synthesis of β,γ-unsatd. amino alcs., e.g. II (R = Me, Ph), is described.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	94.51	95.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.60	-14.60

STN INTERNATIONAL LOGOFF AT 14:45:15 ON 25 OCT 2005